Xeris Biopharma Holdings (XERS) EBITDA (2020 - 2025)
Historic EBITDA for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to $620000.0.
- Xeris Biopharma Holdings' EBITDA rose 10394.33% to $620000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$15.6 million, marking a year-over-year increase of 7519.1%. This contributed to the annual value of -$54.8 million for FY2024, which is 1191.99% up from last year.
- Per Xeris Biopharma Holdings' latest filing, its EBITDA stood at $620000.0 for Q3 2025, which was up 10394.33% from -$1.9 million recorded in Q2 2025.
- In the past 5 years, Xeris Biopharma Holdings' EBITDA registered a high of $620000.0 during Q3 2025, and its lowest value of -$50.8 million during Q4 2021.
- In the last 5 years, Xeris Biopharma Holdings' EBITDA had a median value of -$16.8 million in 2023 and averaged -$18.2 million.
- In the last 5 years, Xeris Biopharma Holdings' EBITDA plummeted by 13186.65% in 2021 and then soared by 10394.33% in 2025.
- Quarter analysis of 5 years shows Xeris Biopharma Holdings' EBITDA stood at -$50.8 million in 2021, then soared by 74.57% to -$12.9 million in 2022, then decreased by 3.48% to -$13.4 million in 2023, then soared by 61.68% to -$5.1 million in 2024, then skyrocketed by 112.1% to $620000.0 in 2025.
- Its EBITDA was $620000.0 in Q3 2025, compared to -$1.9 million in Q2 2025 and -$9.2 million in Q1 2025.